Authors' Reply to Pires et al.: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes"
Drugs
.
2018 Jun;78(8):853-855.
doi: 10.1007/s40265-018-0919-1.
Authors
Hillel P Cohen
1
,
Andrew Blauvelt
2
,
Robert M Rifkin
3
,
Silvio Danese
4
,
Sameer B Gokhale
5
,
Gillian Woollett
6
Affiliations
1
Sandoz Inc., 100 College Road West, Princeton, NJ, 08540, USA. hillel.cohen@sandoz.com.
2
Oregon Medical Research Center, Portland, OR, USA.
3
Rocky Mountain Cancer Centers, Denver, CO, USA.
4
IBD Center-Humanitas Clinical and Research Hospital, Milan, Italy.
5
Novartis Ltd., Hyderabad, India.
6
Avalere Health, Washington, DC, USA.
PMID:
29785563
PMCID:
PMC5993848
DOI:
10.1007/s40265-018-0919-1
No abstract available
Publication types
Comment
MeSH terms
Biosimilar Pharmaceuticals*
Humans
Publications*
Substances
Biosimilar Pharmaceuticals